Form 4: Veracyte CEO Marc Stapley's Equity Holdings Update

Veracyte CEO Marc Stapley reported the vesting of performance-based restricted stock units and subsequent tax-related share disposition, increasing his direct beneficial ownership.

Summary

• CEO Marc Stapley acquired 139,074 shares of Veracyte common stock on February 26, 2026, through the vesting of performance-based restricted stock units (PSUs).
• Of these PSUs, 70,239 vested on February 26, 2026, with the remaining 68,835 scheduled to vest on December 2, 2026, contingent on continuous service.
• The Board of Directors certified the achievement of the performance goals for these PSUs.
• Concurrently, 35,841 shares were disposed of at a price of $38.75 per share to satisfy tax withholding obligations related to the PSU vesting. This was not a sale.
• Following these transactions, Marc Stapley directly beneficially owns 422,532 shares of Veracyte common stock.
• The reported beneficial ownership also includes 696 shares purchased on January 31, 2026, via the Veracyte, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the achievement of performance goals and increased alignment of the CEO's interests with shareholders through higher direct equity ownership.

Positives

• The vesting of 139,074 performance-based restricted stock units indicates that the company's Board of Directors certified the achievement of specific performance goals.
• The CEO's increased direct beneficial ownership, now totaling 422,532 shares, demonstrates continued alignment of management's interests with those of shareholders.
• The inclusion of 696 shares purchased through the Employee Stock Purchase Plan suggests ongoing employee participation and confidence in the company.

Future Outlook

The remaining 68,835 performance-based restricted stock units are scheduled to vest on December 2, 2026, contingent upon the Reporting Person's continuous service to the Issuer through that date.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting of performance-based equity awards, are common forms of executive compensation in the biotechnology and diagnostics industry. These filings provide transparency into management's equity holdings and can signal confidence in the company's future performance, especially when performance goals are certified by the board.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PSUs) for executive compensation aligns with common practices among publicly traded companies in the healthcare and technology sectors, such as Illumina or Guardant Health, which tie executive incentives to specific operational or financial achievements.
• The disposition of shares solely for tax withholding purposes is a standard procedure following equity vesting and is not indicative of a lack of confidence, mirroring practices seen across the S&P 500 for executive compensation plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased insider ownership by the CEO can be viewed positively, signaling management's confidence and alignment with shareholder interests.
• Employees: The Employee Stock Purchase Plan (ESPP) participation indicates a mechanism for broader employee ownership and engagement.

Next Steps

• The remaining 68,835 performance-based restricted stock units are scheduled to vest on December 2, 2026, subject to continuous service.

Key Dates

Keywords

Veracyte, VCYT, Marc Stapley, Insider Transaction, Form 4, Equity Vesting, Restricted Stock Units, CEO Stock Ownership, Employee Stock Purchase Plan